Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.31 |
| ▸ | PRKCG | P05129 | 2/20 | 0.31 |
| ▸ | PRKCB | P05771 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | PRKCH | P24723 | 2/20 | 0.31 |
| ▸ | PRKCI | P41743 | 2/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.31 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712301 | 0.86 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL7203570 | 0.82 | — | — | |
| SCHEMBL11983845 | 0.80 | ALDH1A1 (0.41) | EPHX1 | |
| SCHEMBL256016 | 0.78 | ALDH1A1 (0.50) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL4074204 | 0.78 | — | — | |
| SCHEMBL3862714 | 0.77 | ALDH1A1 (0.30) | — | |
| SCHEMBL11219791 | 0.77 | ALDH1A1 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL20732767 | 0.77 | ALDH1A1 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL712128 | 0.77 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL10300847 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1379513-B1 | PRODRUGS OF COX-2 INHIBITORS | PHARMACIA CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| CN-1098256-C | Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors | SEARLE & CO (US) | 2003-01-08 | — | — | CN | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-6248498-B1 | PHOTOSENSITIVE MODIFIED VINYL ALCOHOL POLYMER GRAFTED WITH FURANYL QUATERNARY HETEROCYCLE FOR HYDROPHOBIC POLYMER | THE CHROMALINE CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-5932598-A | NOVEL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PRODRUGS; ADMINISTERING TO TREAT INFLAMMATION-ASSOCIATED PAIN DUE TO CANCER, DENTAL PAIN; CYCLOOXYGENASE-2 INHIBITORS | G. D. SEARLE & CO. (US) | 1999-08-03 | — | — | US | disclosed |
| CN-1216043-A | Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors | SEARLE & CO (US) | 1999-05-05 | — | — | CN | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | UGT2B7 247/4885PRKD3 3748/4885PRKCG 3669/4885 |
| US-20110009624-A9 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | UGT2B7 247/4885PRKD3 3748/4885PRKCG 3669/4885 |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | UGT2B7 56/4885PRKD3 3897/4885PRKCG 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.